J&J Covid vaccine adds $502 million to third-quarter sales

J&J misses Q3 revenue estimates, raises full-year forecastJohnson & Johnson said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report Tuesday that beat Wall Street’s profit expectations. Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: Adjusted EPS: $2.60 per… Continue reading J&J Covid vaccine adds $502 million to third-quarter sales

J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests

Johnson & Johnson Covid-19 vaccine recipients are better off getting a booster shot from Pfizer or Moderna, a highly anticipated U.S. study suggested Wednesday. The study on “mixing and matching” Covid vaccines included more than 450 adults who have received one of the three regimens currently available in the United States: J&J’s, Moderna’s or Pfizer’s.… Continue reading J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests

Fauci says U.S. will likely resume use of J&J Covid vaccine with a warning or restriction

White House chief medical advisor Dr. Anthony Fauci said Sunday he believes the U.S. will likely resume use of the Johnson & Johnson Covid-19 vaccine with a warning or restriction attached. Health regulators asked states on Tuesday to temporarily halt J&J’s single-dose shot after reports of six cases of rare brain blood clots in women… Continue reading Fauci says U.S. will likely resume use of J&J Covid vaccine with a warning or restriction